Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vistagen Therapeutics Inc
(NQ:
VTGN
)
3.110
+0.030 (+0.97%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vistagen Therapeutics Inc
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q3 2023 Financial Results, Corporate Update
February 08, 2023
Via
Investor Brand Network
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
February 08, 2023
Via
Benzinga
Why Sintx Technologies Shares Are Trading Lower By 38%; Here Are 20 Stocks Moving Premarket
February 08, 2023
Gainers PainReform Ltd. (NASDAQ: PRFX) shares rose 89.5% to $0.9475 in pre-market trading. PainReform reported receipt of extension to Aug. 7, 2023 to meet the Nasdaq's minimum bid price requirement.
Via
Benzinga
Preview: VistaGen Therapeutics's Earnings
February 06, 2023
Via
Benzinga
VistaGen Therapeutics Earnings Perspective: Return On Capital Employed
December 22, 2022
Via
Benzinga
Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results
February 07, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Q3 Fiscal 2023 Results Call and Webcast
February 06, 2023
Via
Investor Brand Network
Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023
February 06, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Closing of Strategic Acquisition
February 02, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition
February 02, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Doses First Participants in PH10 Phase 1 Clinical Trial
January 24, 2023
Via
Investor Brand Network
Exposures
Product Safety
Why AppTech Payments Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
January 31, 2023
Gainers
Via
Benzinga
Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder
January 24, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Set to Commence Antidepressant Nasal Spray Trial This Quarter
January 19, 2023
Via
Investor Brand Network
Exposures
Product Safety
Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In First Quarter Of 2023
January 19, 2023
Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In First Quarter Of 2023
Via
News Direct
Exposures
Product Safety
Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In First Quarter Of 2023
January 19, 2023
By Rachael Green, Benzinga
Via
TheNewswire.com
Exposures
Product Safety
Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In First Quarter Of 2023
January 17, 2023
In the race to create faster-acting, safer antidepressants, Vistagen (NASDAQ: VTGN) is starting the year strong as it gets ready to launch a Phase 1 Trial of its novel pherine nasal spray for Major...
Via
Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Completes 4-Week Treatment Protocol for Final Patient in Phase 2 AjDA Trial
January 10, 2023
Via
Investor Brand Network
Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety
January 10, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Takes Key Steps to Protect, Enhance IP Program
January 03, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Vistagen Advances Intellectual Property Program to Expand Patent Protection for PH94B to Include Treatment of Adjustment Disorder
December 30, 2022
From
Vistagen
Via
Business Wire
Why Cal-Maine Foods Shares Are Trading Lower; Here Are 24 Stocks Moving Premarket
December 29, 2022
Gainers Quotient Limited (NASDAQ: QTNT) shares rose 125% to $0.54 in pre-market trading after dropping around 38% on Wednesday. Quotient recently announced the intent to voluntary delist from the...
Via
Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Plans to Acquire Pherin Pharmaceuticals Inc.
December 21, 2022
Via
Investor Brand Network
Vistagen Strengthens Its Neurology Focused Pipeline With Pherin Pharma Acquisition
December 21, 2022
Via
Benzinga
Vistagen to Acquire Pherin Pharmaceuticals
December 21, 2022
From
Vistagen
Via
Business Wire
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
December 19, 2022
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
December 19, 2022
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 19, 2022
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
December 16, 2022
Via
Benzinga
KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing
December 16, 2022
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.